We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
2
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2013
Completed
1
50.0%
Recruiting
No approval data available
- TearSolutions received FDA Orphan Drug and Fast Track designations for Lacripep, a first-in-class synthetic peptide therapy for neurotrophic keratitis (NK), a rare degenerative corneal disease. - The company has initiated a multicenter, randomized, vehicle-controlled Phase 2 clinical trial (NCT07568730) enrolling approximately 54 patients with Stage 1 NK across three U.S. sites. - Lacripep is a synthetic 10-amino acid fragment of the human tear protein lacritin, designed to repair corneal epithelium and restore sensory nerve function via topical eye drop administration. - Prior Phase 1/2 data in primary Sjögren's Syndrome showed rapid improvement in corneal health and symptom reduction as early as two weeks.
